Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Episode 1 February 28, 2022 00:13:11
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022
COR2ED Medical Education
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Feb 28 2022 | 00:13:11

/

Show Notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Other Episodes

Episode 1

December 14, 2022 00:19:51
Episode Cover

Clinical implementation of targeted and immunotherapies for advanced RCC

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of...

Listen

Episode 2

July 04, 2022 00:19:34
Episode Cover

PBC highlights from ILC 2022: ep.2

COR2ED Medical Education: In this podcast episode, Prof. Kris Kowdley, Director, Liver Institute Northwest, Washington State University, USA and Prof. Jörn Schattenberg, Director, Metabolic...

Listen

Episode 2

February 02, 2023 00:24:10
Episode Cover

Update from ASCO GI 2023 Ep 2: lower GI cancer highlights

COR2ED Medical Education: This episode, covers the highlights on colorectal cancer from ASCO GI 2023.  Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and...

Listen